Arthritis Clinical Trials in Dallas

View 70 new treatments for Arthritis in Dallas, TX, and nearby areas, such as Allen, Arlington, Carrollton, Denton, Frisco, Garland, Grand Prairie, Irving, Lewisville, McKinney and Mesquite. Every day, Power helps hundreds of arthritis patients connect with leading medical research.
View 59 trials in Dallas
Filter (59)

COVID-19 VaccinE Response in Rheumatology Patients

Research Clinic, Dallas + 1 more

This trial tests an extra dose of the COVID-19 vaccine in patients with autoimmune diseases. It aims to see if pausing their medications temporarily can make the vaccine more effective. The goal is to improve their immune response to COVID-19.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Jeffrey R Curtis, MD MS MPH
Principal Investigator

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Fort Worth + 6 more

This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Baricitinib for Rheumatoid Arthritis

Eli Lilly Clinic, Red Oak + 7 more

This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

TG-C for Knee Osteoarthritis

Kolon TissueGene Clinic, Dallas + 7 more

This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
David W Romness, MD
Principal Investigator

Bimekizumab for Psoriatic Arthritis

UCB Biopharma Clinic, Mesquite + 1 more

This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
UCB Cares
Study Director

Tildrakizumab for Psoriatic Arthritis

Sun Clinic, Grapevine + 1 more

This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Upadacitinib for Axial Spondyloarthritis

AbbVie Clinic, Fort Worth + 4 more

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director

Upadacitinib for Psoriatic Arthritis

AbbVie Clinic, Dallas + 2 more

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
AbbVie Inc.
Study Director

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, Colleyville + 5 more

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 6 - 12 Weeks
AbbVie Inc.
Study Director

Deucravacitinib for Psoriatic Arthritis

Bristol-Myers Squibb Clinic, Allen + 7 more

This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
Page 1 of 6

Frequently Asked Questions

How much do arthritis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do arthritis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across arthritis trials in Dallas, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for arthritis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Dallas is research being conducted for arthritis?

Prominent clinical trials for arthritis in Dallas are being conducted at the Metroplex Clinical Research Center, with approximately 9 trials ongoing. These trials are primarily located in the northern part of the city as of 2024.

What promising new drugs are being tested?

In Dallas, arthritis research is focusing on treatments like Janus Kinase (JAK) Inhibitors and Immunomodulatory Therapies. Notable drugs being studied include Upadacitinib, Adalimumab, and Baricitinib.